Abstract We evaluated midlife risk factors of developing type 2 diabetes mellitus (T2DM) in late life in a population-based study of older persons. A cohort of 2,251 persons, aged 65-96, participated in AGES-Reykjavik in 2002 -2004 ; all attended the Reykjavik Study 26 years earlier, at the mean age of 50. Based on glucometabolic status in 2002-2004 the participants are divided into a normoglycemic control group (n = 1,695), an impaired fasting glucose (IFG) group (n = 313) and T2DM group (n = 243). Change in risk parameters from midlife is evaluated retrospectively in these three groups. Since examined earlier 14.3% of men and 8.2% of women developed T2DM. A family history of diabetes was reported in 39.5% of T2DM compared to 19.3% in both IFG and normoglycemics. The T2DM and IFG groups currently have higher levels of fasting triglycerides, greater body mass index (BMI) and higher systolic blood pressure than normoglycemics and this difference was already apparent in midlife. In late life, two or more metabolic syndrome criteria are present in 60% of the T2DM groups compared to 25% in normoglycemic groups. T2DM with impaired cardiovascular health is more marked in women than men when compared with normoglycemics. Family history and higher levels of BMI, triglycerides and systolic blood pressure in midlife are associated with the development of T2DM in late life, suggesting risk can be evaluated long before onset. A continued rise in risk factors throughout life allows for more aggressive measures in preventing or delaying development of T2DM and its effect on cardiovascular health.
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Introduction
Type 2 diabetes is currently recognized as one of the main threats to human health worldwide [1] and the prevalence of the disease keeps increasing in an epidemic fashion. It is well recognized that development of the T2DM is influenced by both genetic and environmental factors [2] and that onset can be prevented or delayed by lifestyle modification [3, 4] . Identifying people at risk of developing T2DM as early as possible is therefore of great importance in effective primary prevention strategies. Several predictive models have been designed for detecting short term risk of developing T2DM, some of these models are highly sophisticated [5] , whereas others are relatively simple and easy to use in general practice [6] . The metabolic syndrome has also been used to predict both T2DM [7] and CVD [8] as in the cross-sectional data from the NHANES III where the prevalence of metabolic syndrome (NCEP criteria) was very high among people, 50 years and older, with diabetes and those with diabetes and metabolic syndrome had the highest prevalence of CHD [9] . Most of the prediction models have taken into account risk factors such as family history, age, BMI, hypertension, high blood glucose and some also use high TG and low HDL cholesterol levels. Recent studies have in addition focused on the association between T2DM and low-grade systemic inflammation [10] , where the pathophysiology seems to be largely attributable to insulin resistance with high blood levels of fatty acids [11] .
Not many studies have, however, analysed long term risk of developing T2DM, before glucometabolic impairment is detected. In the present work we have assessed changes in risk parameters, some of which are also known risk factors for cardiovascular disease, associated with the development of diabetes over a mean period of 26 years. The following questions regarding the development of T2DM in the Age, Gene/Environment SusceptibilityReykjavik Study will be addressed:
1. Can the risk of developing T2DM in late life be detected already in midlife?
2. Is cardiovascular disease more common in older persons with T2DM or IFG than in normoglycemics?
Subjects and methods
Study population
The study cohort consists of men and women who participated in the AGES-Reykjavik Study between 2002 and 2004 [12] . The study is a continuation of a populationbased Reykjavik Study, initiated in 1967 by the Icelandic Heart Association, as described in detail by Jonsdottir et al. [13] .
As part of the AGES-Reykjavik examination, a comprehensive questionnaire is administered. It includes questions regarding diabetes in close relatives as well as own health history, including cardiovascular events and stroke. Participants were asked to bring all medications and supplements used in the previous 2 weeks to the clinic. All participants had fasting blood specimens drawn that were analyzed as documented below. They also brought urinary morning samples to the clinic. Midlife data from the Reykjavik Study are also reported.
We divided the study cohort into three subgroups for both genders, according to their current glycemic status, based on the WHO recommendations from 1999 [14] . The first group, used as reference, were normoglycemic (fasting glucose B 6.0 mmol/l). The second group had impaired fasting glucose values at the AGES-Reykjavik examination (6.1-6.9 mmol/l). The third group, the T2DM, was either diagnosed upon their visit to the clinic with fasting serum glucose of C7 mmol/l, or identified by self-reported diabetes in the questionnaire, use of diabetes medication, or being on a special diet for T2DM and under regular observation of health professionals. From the original study cohort of 2,300 individuals, 21 were excluded as they either gave conflicting information about having diabetes, or the questionnaire related to diabetes was not completed. We also excluded 28 subjects who were already diagnosed with T2DM when first attending the Reykjavik Study. The study population therefore consists of 2,251 individuals, 956 men and 1,295 women, aged 65-96, with an overall response rate of 75% for men and 68% for women. The mean age of the AGES-Reykjavik cohort when first entering the Reykjavik Study was 50 years.
Risk factor ascertainment
In the AGES-Reykjavik Study, glucose, total cholesterol, HDL cholesterol, triglycerides, high sensitivity CRP, HbA 1c as well as urinary albumin and creatinine were measured on a Hitachi 912, using reagents from Roche Diagnostics and following the manufacturer's instructions. Insulin was measured by an electrochemiluminescence immunoassay on a Roche Elecsys 2010 instrument, using two monoclonal antibodies and a sandwich principle. The method was standardized using the first IRP WHO Reference Standard 66/304 (NIBSC). The analytical methods used in the Reykjavik Study have been described elsewhere [13] . HOMA IR , a measure of the insulin resistance, is calculated using the formula [insulin (mU/l) 9 glucose (mmol/l)]/22.5 [15] .
Blood pressure was measured with a mercury sphygmomanometer, with a large cuff, the mean value of two consecutive blood pressure measurements being used. A 12 lead resting ECG was evaluated according to the Minnesota code [16] . The coronary events are self-reported but verified by hospital records on myocardial infarction (ICD-10: I21), coronary artery bypass graft, and percutaneous transluminal coronary intervention categorizes according to the NOMESCO classification for Surgical Procedures. The information is collected from National Health System Records by the Icelandic Heart Association.
Metabolic syndrome criteria, as defined by WHO, were estimated [17] . As current glucometabolic status is used to divide the cohort into study groups we decided to omit insulin resistance and glycemic status, and include two or more of the following criteria: BMI [ 30 kg/m 2 ; triglycerides C 1.7 mmol/l or HDL \ 0.9, in males, and \ 1.0 mmol/l, in females; hypertension [ 140/90 mmHg; U-albumin/creatinine C 3.5 mg/mmol.
Informed consent was obtained from all participants and the study was approved by the National Bioethics Committee in Iceland (VSN 00-063) as well as the Institutional Review Board of the Intramural Research Program of the National Institute on Aging and the Data Protection Authority in Iceland.
Statistical analyses
Response variables on a continuous scale were analysed with linear regression models by sex, adjusted for age and a categorical predictor for glycemic status. Binary variables were analysed similarly with logistic regression models. TG and CRP were log-transformed. Analyses of change in continuous variables were performed, using mixed effects regression models, adjusted for age and time between visits and a random effect for subjects. The change in BMI, blood pressure and lipids over a mean period of over 26 years was calculated. All parameters were adjusted to the age of 50 in midlife and a 26 year follow-up. The association of late life T2DM with midlife risk parameters was estimated in a multivariable logistic regression model. We analyzed the data using SAS/STAT Ò software, version 9.1.
Results
The study cohort is categorized into subgroups by gender and present glycemic status as described above. Mean age when entering the AGES-Reykjavik is similar in all subgroups (Table 1) with an age range of 65-96 for both genders. From the mean age of 50, 14.3% of men developed T2DM over the 26 year study period, compared with 8.2% in women. The mean age at T2DM onset based on self report was 69 (SD ± 10) years in both genders. Of the total T2DM group (n = 243), 174 had been diagnosed with the disease between their examination in midlife and participation in the AGES-Reykjavik; those diagnosed by screening as part of the study (n = 69) were about a year older than the mean age of the cohort. Despite this the undiagnosed T2DM group did not show any distinct characteristics different from those already diagnosed so all T2DM participants are treated as one group in this study. A positive family history of diabetes is reported by 39.5% of participants with T2DM, compared with 19.3% in the IFG and normoglycemic groups (Table 1) .
Change in risk parameters from midlife to late life Based on glycemic status of participants in late life, we examined retrospectively the change in BMI, blood pressure and fasting serum lipids over a mean period of 26 years, as illustrated in Fig. 1 . In midlife (Table 2 ) the mean BMI in both men and women that develop T2DM is significantly higher than in normoglycemics. A significant increase in BMI with age is observed in all study groups (P \ 0.0001), with a greater weight gain seen in the IFG and T2DM study groups than in the normoglycemics (P \ 0.0001 for men and \0.0005 for women). In men the increase of mean BMI in the IFG and T2DM groups was 1.8 and 1.6 kg/m 2 but 3.3 and 2.7 kg/m 2 in respective groups of women. Mean BMI in the normoglycemic group of men increased by 1.0 but in women by 2.3 kg/m 2 over the study period (Fig. 1a) .
Men that developed IFG and T2DM had significantly higher mean systolic blood pressure (P \ 0.0001) in midlife than men remaining normoglycemic throughout the study period (Fig. 1b) . Although women have a significantly lower systolic blood pressure in midlife than men, women who developed IFG and T2DM had significantly higher mean systolic blood pressure in midlife than women remaining normoglycemic (Table 2) .
Both men and women developing IFG and T2DM in late life have significantly higher TG levels in midlife than the respective normoglycemics (P \ 0.0001) as shown in Table 2 and Fig. 1c . All subgroups of women show a highly significant increase (P \ 0.0001) in TG levels over the 26 years, but this is not so in men. The AGES-Reykjavik Study cohort divided into subgroups by glycemic status, as well as by gender Total T2DM is also shown divided into diagnosed (dT2DM) and undiagnosed (uT2DM) groups
The age in years ± SD is given and also the percentage of reporting family history of T2DM for both genders Odds ratios for the association of T2DM in late life with midlife risk parameters are summarized in Table 3 ; they are estimated using a multivariable logistic regression model with adjustment for sex and age at entry in the Reykjavik Study. Variables are listed by the strength of the association.
No difference is seen in cholesterol levels in midlife between study groups. In late life cholesterol has decreased significantly (P \ 0.0001) in all subgroups. However in line with greater proportion of men taking statins (Table 4) the drop in cholesterol level is considerably greater in men than women. In both genders the mean late life cholesterol of the T2DM group is significantly lower (P \ 0.001) than in the normoglycemic group (Table 4) .
Glucometabolic status and cardiovascular measures in late life
In late life the glucometabolic status in each study group is assessed by mean values of fasting serum glucose and insulin, with the calculated HOMA IR and blood HbA 1c (Table 4) . A highly significant difference is found in fasting insulin levels and HOMA IR between the normoglycemic and the groups with impaired glucose regulation, but the level in the diabetics is not significantly different from the IFG groups. As expected a stepwise increase is observed in HbA 1c values, increasing from the normoglycemic to the IFG and the diabetic groups. Diabetic medication in the groups diagnosed with T2DM is also shown in the table.
In late life BMI, TG and hypertension are significantly higher in the T2DM groups than in normoglycemics as was already apparent in midlife. The same is true for the IFG groups although the risk factors do not reach the same level as in the T2DM groups. The WHO metabolic syndrome criteria (with glucose level and insulin resistance omitted) reflect this situation, as about 60% of the T2DM groups and almost 50% of the IFG groups have two or more MS criteria, compared to 25% of persons in the normoglycemic subgroups (Table 4) .
Selected indicators of cardiovascular impairment along with CRP levels measured in late life are shown in Table 5 . Over 35% of men report a CVD event (cardiovascular disease and stroke) with no significant difference between study groups. A significantly higher proportion of T2DM men report heart failure (P \ 0.001) than normoglycemics Glucose (mmol/l) 5.3 ± 0.5 5.6 ± 0.5*** 5.7 ± 0.6*** 5.1 ± 0.5 5.4 ± 0.6*** 5.4 ± 0.6*** IFG % (n) 0.6 (4) Glycemic groups according to current glycemic status, based on WHO recommendations from 1999 [14] All values are from the midlife entry in the Reykjavik Study and are mean ± SD unless otherwise indicated
Significance estimates: ** P \ 0.01; *** P \ 0.001 for age-adjusted comparison among the study groups a Median and (quartile range) and similarly a significantly higher proportion have an abnormal ECG (P \ 0.01). A similar trend is seen for the adjudicated CE from health records. No significant difference is seen in current CRP levels in the three study groups of men. In contrast a significant increase in CRP levels is seen in women when going from normoglycemics to IFG and T2DM groups. Women report a considerably lower prevalence of CVD than men in all subgroups, but women with T2DM have a significantly higher prevalence (P \ 0.05) of both selfreported CVD and adjudicated CE from health records compared to IFG and normoglycemic women. No significant difference, however, is seen in abnormal ECG in the three study groups of women.
Discussion
The data shown here reflect the status of glucometabolic regulation and cardiovascular health in older persons in the AGES-Reykjavik Study. The major findings are that family history and elevated levels of BMI, TG and systolic blood pressure in midlife are associated with the development of T2DM in late life. As levels of these parameters continue to rise with age, the differences between the three study groups, T2DM, IFG and normoglycemics, already apparent in midlife, are maintained throughout the study period.
Others have shown in short term prediction studies that high blood glucose, high BMI and high systolic blood pressure are risk factors for T2DM development [6, 7] , but TG levels have not been greatly emphasized. Recently, however, elevated TG levels, linked to insulin resistance have been considered as a risk factor for T2DM [17] . In midlife men have higher levels of TG than women, but TG levels in women rise with age and reach about the same level as men at the age of 65 years [18] . In our study high TG levels are seen to precede impairment in glucose regulation, an observation that could be used in predicting the risk of developing T2DM earlier than before. Monitoring 
Glucose (mmol/l) 5.4 ± 0.4 6.4 ± 0.2*** 7.9 ± 1.8*** 5.3 ± 0.4 6.4 ± 0.2*** 7.5 ± 1.8*** Insulin (mU/l) a 8.6 ± 5.8 12.9 ± 6.1*** 15.7 ± 10.3*** 8.3 ± 5.4 14.6 ± 9.2*** 14.9 ± 9.2*** HOMA-IR 2.2 ± 1.8 4.3 ± 4.6*** 6.7 ± 7.4*** 2.0 ± 1.5 4.2 ± 2.9*** 5.3 ± 4.1*** HbA 1c (%) 5.6 ± 0.3 5.8 ± 0.3*** 6.6 ± 0.8*** 5.7 ± 0.3 5.9 ± 0.4*** 6.3 ± 0.7*** Glycemic groups, based on WHO recommendations from 1999 [14] . All values shown are mean ± SD unless otherwise indicated Significance estimates: * P \ 0.05; ** P \ 0.01; *** P \ 0.001 for age-adjusted comparison among the study groups a For insulin the truncated mean is used, excluding values [60 mU/L b Median and (quartile range)
c With two or more of the metabolic syndrome criteria, other than insulin resistance and glycemic status, as listed in Subjects and methods; i.e. BMI, TG, HDL, HT, U-albumin/creatinine [17] TG levels in people with elevated BMI and BP might be an additional tool in estimating the risk of developing T2DM, years before elevation in glucose levels is detected.
Other findings are that prevalence of T2DM in the study cohort as a whole is 11.6%, including those that were diagnosed with T2DM between the mean ages of 40-49 years. This is low for the age group 65-96, compared with prevalence of over 20% in adults older than 65 years in US [19, 20] . Less than one-third of the diabetic group was undiagnosed prior to entering the study, which also is low compared with US estimates, where equivalent numbers are under medical treatment for diabetes as those undiagnosed in the community. Another finding is that men in AGESReykjavik show both higher prevalence and receive more intensive glucose lowering treatment than women judged from the medication profile of hypoglycaemic drugs. Similar observations have been reported from the Icelandic diabetic clinics [21] . In the DECODE study [22] the prevalence of diagnosed diabetes did not differ between men and women except in people over the age of 80 where the prevalence in women was higher. When compared with prevalence of diabetes in Europe, Icelanders are shown to be at the lower end of the scale [22, 23] . Prevalence of T2DM has, however, been rising in the general population of Iceland over the last several years [24] as in other areas of the world, because of increased incidence in the lower age groups and increase in longevity of those diagnosed with T2DM. Prevalence in the 70-88 years old has, however remained the same for at least 10 years, or 12% as calculated from the Reykjavik Study in 1993. A different situation has been observed in southern Sweden, where the incidence and age at diagnosis remained constant at the same time as prevalence increased considerably [25] . Cardiovascular disease is strongly associated with diabetes and is one of the more severe co-morbidities of the disease. CRP, a marker for low systemic inflammation is one of the cardiovascular risk factors, but has recently also been linked to T2DM, more so in women than in men [10] . Men that develop IFG or T2DM in the AGES-Reykjavik cohort do not, however, report higher incidence of CVD than normoglycemics, nor is there any significant difference in CRP levels between the three study groups in late life. A possible explanation is that men with the most severe CVD and T2DM have not survived. T2DM women on the other hand show higher CRP levels than normoglycemic women and report significantly higher prevalence of CVD (P \ 0.05). The high CRP level in T2DM women reflects a higher level of systemic inflammation, possibly associated with high BMI [26] but may also indicate a more severe CVD, compared to normoglycemic women. In recent studies diabetes has been shown to have a greater impact on CHD mortality risk in women than in men [27] and meta-analysis of 37 prospective cohort studies showed diabetic women with a 50% higher relative risk for fatal coronary heart disease than diabetic men [28] .
The participation rate of 75% among men and 68% for women in the AGES-Reykjavik is high and when asked, the non-responders gave the reason they did not feel up to attending. This suggests that the most disabled people did not participate, in spite of the fact they were offered a home visit. Midlife data show that the non-responders had a higher mean value of systolic blood pressure (men 143 vs. 136 and women 133 vs. 127 mmHg), but had similar values in glucose, BMI and TG [12] . This indicates that our risk factor associations would most likely have been even stronger with higher participation rate. A weakness of this Glycemic groups based on WHO recommendations from 1999 [14] Significance estimates: * P \ 0.05; ** P \ 0.01; *** P \ 0.001 for age-adjusted comparison among the study groups using age-adjusted logistic regression and v 2 analysis for MI and AF in women a Median and (quartile range) b CVD self-reported stroke, transient ischemic attack (TIA) and cardiac event study is that survival analyses have not been completed so the impact from loss of follow up is unknown. In summary family history of diabetes, elevated levels of BMI, TG, and systolic blood pressure in midlife are associated with the development of IFG and T2DM in late life. Our data show a continued rise in these risk parameters over the study period opening a possibility of predicting the risk of developing T2DM decades before onset. The campaign for health promotion and prevention strategies might accordingly start quite early in life by assessing risk parameters in the hope of preventing or delaying development of T2DM and its detrimental effect on cardiovascular health.
